Palvella Therapeutics (PVLA) Free Cash Flow (2016 - 2026)
Palvella Therapeutics has reported Free Cash Flow over the past 10 years, most recently at -$12.9 million for Q4 2022.
- Quarterly Free Cash Flow fell 8.65% to -$12.9 million in Q4 2022 from the year-ago period, while the trailing twelve-month figure was -$61.0 million through Dec 2022, down 608.25% year-over-year, with the annual reading at -$25.0 million for FY2025, 130.68% down from the prior year.
- Free Cash Flow was -$12.9 million for Q4 2022 at Palvella Therapeutics, down from -$8.8 million in the prior quarter.
- Over five years, Free Cash Flow peaked at $30.9 million in Q1 2018 and troughed at -$23.0 million in Q1 2022.
- The 5-year median for Free Cash Flow is -$12.5 million (2019), against an average of -$8.8 million.
- Year-over-year, Free Cash Flow surged 373.8% in 2021 and then tumbled 154.61% in 2022.
- A 5-year view of Free Cash Flow shows it stood at -$9.6 million in 2018, then plummeted by 57.44% to -$15.2 million in 2019, then increased by 7.62% to -$14.0 million in 2020, then increased by 15.02% to -$11.9 million in 2021, then dropped by 8.65% to -$12.9 million in 2022.
- Per Business Quant, the three most recent readings for PVLA's Free Cash Flow are -$12.9 million (Q4 2022), -$8.8 million (Q3 2022), and -$16.2 million (Q2 2022).